Frontenac, a Chicago-based private equity firm, has acquired NutriScience Innovations, a leading provider of science-backed ingredients for the nutraceutical, functional food and beverage, and animal health industries. The acquisition closed on August 5, 2026.

AcquirerFrontenac (United States, Chicago)
TargetNutriScience Innovations (United States, Fairfield)
Deal typeAcquisition
Stake acquired100%
Close date2026-08-05
Announcement date2026-08-05
Buy-side financial advisorsCascadia Capital
Sell-side financial advisorsCascadia Capital, Lazard
Legal advisors buy sideWinston Strawn
Legal advisors sell sideSquire Patton Boggs

The deal strengthens Frontenac’s position in the specialty ingredients segment, aligning with its broader strategy to invest in consumer-focused companies. NutriScience Innovations has a 20-year track record of developing high-quality, science-backed ingredients for diverse markets.

Deal Mechanics

The acquisition was facilitated by Cascadia Capital as the buy-side financial advisor and Lazard on the sell side. Legal advice to Frontenac came from Winston Strawn, while Squire Patton Boggs represented NutriScience Innovations.

NutriScience’s expertise in delivering innovative ingredients with scientific backing complements Frontenac’s focus on building scalable platforms within the consumer sector. The acquisition is expected to bolster Frontenac's portfolio of companies such as Monterey Bay Herb Co., CCI Prime, and Navis Food Partners.

Financial Context

The terms of the deal were not disclosed. However, the strategic importance of NutriScience Innovations is evident from its long-standing reputation in the specialty ingredients market and its alignment with Frontenac’s investment criteria.

This acquisition reflects a significant move by Frontenac to expand its presence in the consumer sector through targeted investments in companies that drive innovation and growth within specific niche markets. NutriScience Innovations’ scientific approach to ingredient development is anticipated to contribute to Frontenac's portfolio value.